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The clinical application of antisense oligonucleotides (ASOs) is becoming more of a reality as several drugs have
been approved for the treatment of human disorders and many others are in various phases in development and
clinical trials. ASOs are short DNA/RNA oligos which are heavily modified to increase their stability in
biological fluids and retain the properties of creating RNA-RNA and DNA-RNA duplexes that knock-down or
correct genetic expression. This review outlines several strategies that ASOs utilize for the treatment of various
congenital diseases and syndromes that develop with aging. In addition, we discuss some of the mechanisms for
specific non-targeted ASO internalization within cells.
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Introduction

translation or sequester endogenous microRNAs [2] (Fig. 1).

One of the growing fields of interest pertaining to nucleic
acid-based gene silencing/modification is the application of
antisense oligonucleotides (ASOs). ASOs are chemically
modified nucleic acid sequences that serve as highly
selective sequence pairs to specific regions of mRNA and
regulate the translation of genetic material into functional
proteins. ASOs bind complementary RNA by Watson-Crick
base pairing and can suppress gene expression via a number
of distinct antisense mechanisms. ASOs which contain
stretches of >5 DNA nucleotides activate the RNase H
antisense mechanism. RNaseH1 is a ubiquitously expressed
endonuclease which selectively cleaves the RNA strand of a
DNA/RNA heteroduplex [1]. ASOs of other chemical
compositions can bind RNA to modulate splicing, arrest

The phosphodiester (PO) backbone of DNA and RNA is
susceptible to nuclease mediated degradation which limits
application of unmodified oligonucleotides as therapeutics.
In contrast, chemical modifications of the backbone enhance
the metabolic stability of oligonucleotides which enables
their use for therapeutic applications. One of the most widely
used modifications in oligonucleotide therapeutics is the
phosphorothioate modification [3]. The phosphorothioate (PS)
modification replaces a non-bridging oxygen atoms in the PO
linkage with a sulfur atom. This increases ASO stability in
biological fluids and also enhances their protein binding and
cell uptake properties [4]. ASO stability is essential for the
molecules to not only remain intact while in circulation, but
also to be biologically active and internalized into the cell for
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Figure 1. RNase H mediated destruction of targeted mRNA. ASOs are internalized in the cells by several mechanisms
(clathrin/caveolin-mediated endocytosis, micropinocytosis, etc.) in which a small subset of the ASOs escape into the cytoplasm and/or
nucleus. Hybridization of the ASO with complementary hnRNA or mRNA induces RNase H cleavage of the RNA while leaving the ASO
intact for subsequent hybridizations.

gene silencing. However, this mechanism may only work if
the ASO successfully navigates past the cell
plasma/endosomal membranes to target the specific mRNA
of interest. The mechanism for ASO internalization is not
well understood, though it is thought that efficient uptake
involves specific protein receptors [5, 6]. At the present time, it
is believed that clathrin-mediated endocytic receptor(s)
allows ASO internalization at concentrations in the nM-µM
range [6-8].
Recent works focused on increasing the understanding of
these drugs have enabled great strides in the therapeutic
application. The FDA approved ASO therapeutic uses such
as treatment for familial hypocholesteremia, with many
others in phase III clinical trials [9-11]. New designs are
constantly being developed to increase effectiveness of these
drugs, as well as new approaches to different diseases, while
at the same time decreasing potential off-target side-effects [6,
12]
. The focus of this review is to highlight the development
of ASOs in clinical drug development for a variety of
diseases, as well as examine recent research to answer
fundamental questions of cellular ASO internalization and
systemic clearance.

Backbone Modifications for single stranded ASOs
One key aspect of ASO stability and functionality is
derived from the modifications on the phosphate backbone of
the nucleotide sequence. Second generation ASOs are
comprised of a central gap region of PS DNA flanked on
either ends with 2’-methoxyethyl RNA (MOE) nucleotides.
The MOE nucleotides enhance binding affinity for
complementary RNA and further enhance metabolic stability
which results in longer effectiveness in the clinic [3, 13]. Other
ASO backbone structures such as phosphodiester (PO) or
methylphosphonates (MP) have been explored [14], but the PS
backbone modifications to have high stability both in-vitro
and in-vivo systems [6], in addition to in-vivo internalization
[15]
for single stranded ASOs.
MP oligonucleotides, which have reduced charge, have
higher nuclease stability than PS-ASOs [16]. However, the
lack of charge on the MP molecule reduces protein binding
and cellular uptake [17-19]. Novel techniques are being utilized
to increase the activity of ASOs, with a majority of clinical
drugs having a PS-2’-methoxyethyl (2’-MOE) modification
of the ribose sugar which increases the Tm of RNA by 2o C
for each modification, while also aiding to reduce access to
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Figure 2. Backbone structures of ASO modifications. A. Unmodified phosphodiester
backbone. B. Generation 1 phosphorothioate (PS-ASO) modification. C. Generation 2
2’-methoxyethyl phosphorothioate (2’ MOE-PS-ASO) modification.

the linkage of the backbone [2] (Fig. 2). It is important to note
that while PS-ASOs are currently being utilized based on
their increased activity, the PS modifications are relatively
easy to synthesize compared to other phosphate
modifications [19]. Currently, over 35 ASOs are in clinical
development, and of these, at least a majority contain PS
backbone structures, and many newer chemical structures
contain 2’-MOE modifications as well [2].
Diseases Targeted by ASOs
Duchenne’s muscular dystrophy
Duchenne’s muscular dystrophy (DMD) is a rare but
debilitating X-linked disease causing muscle wasting by
mutations arising from the DMD gene, which codes for
dystrophin. This protein has been determined to connect the
sub-sarcolemmal cytoskeleton to the extra-cellular matrix
(ECM). Dystrophin, along with the dystrophin associated
glycoprotein complex (DGC) work to stabilize muscle fibers
during muscle contraction from the binding of the
cytoskeleton to the ECM. When this protein is lost due to the
DMD gene mutations, it leads to muscle degeneration,
inflammation, and overall progression of DMD [20]. This
disease is the most common fatal neuromuscular disorder
found in children, which affects 1 in 3,500 males [20]. Patients
are traditionally treated by the age of 5 to prevent premature
death when diagnosed at an early age. Although if left
untreated (without preventative measures), children often
suffer from cardiac or respiratory failure leading to death
before the age of twenty [20-22]. The disease is caused by
genetic missense or nonsense mutations in the open reading
frame of the DMD gene, dystrophin [22].
Antisense oligonucleotides may utilize multiple splicing
mechanisms for when a gene is mistranslated including exon
skipping, cryptic splicing restoration, or even changing levels

of alternate gene splicing [23]. One of the early ASOs used in
DMD treatment, PRO-051, or Drisapersen, utilized exon
splicing modulation for exon 51 (of the 79 exons present) of
Dystrophin to force skip this exon, allowing for rescue of the
ORF [24]. Although it proceeded into stage III of clinical
trials, it failed to be awarded FDA approval due to the high
doses required for effective treatment and long-term toxicity
side-effects [25]. Drisapersen was a modified 2’O-Me RNA
modification. A second drug was developed with a
morpholino backbone [2], which utilizes excision of the
pre-mRNA splicing of dystrophin’s exon 51 [26] based on the
same rescue of the ORF as Drisapersen. The mechanism of a
morpholino modified ASO allows for hybridization binding
to exon 51, which when bound does not allow the splicing
machinery to recognize it, allowing for the ORF to remain
intact, while removing the mutated region [23] (Fig. 3A).
Currently, this drug is in stage III clinical trials and has
demonstrated lower toxicity than its 2’ O-Me counterpart.
Although further testing is required before FDA approval,
there seems to be hope that this morpholino-based ASO will
help in future treatments of DMD, based on the
improvements from the previous 2’ O-Me drug.
Spinal Muscular Atrophy
Spinal muscular atrophy (SMA), not to be confused with
spinal muscular dystrophy, is currently the leading cause of
genetic infant mortality. This disease causes motor neurons
in the central nervous system to decay and lose function [27].
Loss of neuromuscular junctions causes muscles to weaken
and atrophy over time. The loss of muscle function can have
devastating secondary impacts from sleeplessness to
scoliosis, joint contractures, and respiratory failure. This
genetic disorder arises from mutations on exon 7 of the
SMN1 gene, which codes for the survival motor neuron
proteins, with 95-98% of patients displaying a homozygous
trait of this gene [27]. SMN proteins localize to the cytosol
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Figure 3. Exon skipping as a mechanism for “gene” correction. A. The ASO mechanism for the treatment of Duchenne’s Muscular
Dystrophy (DMD) in which the ASO binds to exon 51 containing the mutation and force skips the exon in transcription producing a slightly
shorter but active gene product. B. In cases of Spinal Muscular Atrophy (SMA), heterogenous nuclear ribonuclear proteins (hnRNPs) bind
to exon 7 and prevent further hnRNA modification and subsequent translation. C. SMA treatment with a 2’-methoxyethyl (2’-MOE) modified
ASO (ASO-10-27) displaces hnRNPs and allows translation of the full-length gene product. D. SMA treatment with a 2’-Fluoro (2’-F)
modified ASO recruits Interleukin Enhancer 2 and 3 proteins which displace hnRNPs and allow for the translation of a shorter mRNA
producing a smaller protein product that is still partially active. Figure adapted and modified from Aartsma-Rus et al. [23] and Rigo et al.
[35]

and nucleus, where they are involved in a multiprotein
complex. These proteins are involved in RNP complex
formation, and have been shown to accumulate in Cajal
bodies [28, 29]. SMN2 is also involved in this disease,

however, the copy number increases in the presence of
SMN1 mutations, leading to phenotype modifications.
Currently, there is no specific treatment for the disease
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itself, as most therapies are for treating the symptoms [30].
One potential therapy, proposed a decade ago, was to utilize
quinizoline derivatives as a potential mechanism for
increasing SMN2 promoter activity to induce SMN splicing
patterns to relieve the mutated gene [31]. A study, compiling
multiple compounds that increased SMN promotor activity
identified these derivatives as a potential target with a 2.5
fold increase in activity [32]. Although this mechanism did
produce improvement of motor function in mouse models, a
work-stop was issued and the drug company has canceled
clinical phase II testing [33, 34].
Modulating splicing of mRNA can also be accomplishes
using ASOs. This class utilizes pre-messenger RNA as a
source for correcting an aberrant mRNA product. When
untreated
with
ASOs
heterogenous
nuclear
ribonuclearproteins (hnRNPs) are recruited to the exon to
silence the targeted region [35]. One example for treatment to
inhibit hnRNP activation of pre-mRNA in SMA is
ASO-10-27, which works to provide corrected SMN
expression via a gene splicing mechanism similar to that of
the DMD example [23, 36] (Fig. 3B-D). ASO-10-27 is a
generation 2 drug that is used to boost functional SMN
production by careful splice modification of SMN2, based on
its paralogous gene similarity to SMN1 [33, 36]. The key
mechanism for this ASO is when bound, it does not allow for
hnRNP to bind to the targeted exon 7 by blocking the
binding site, allowing for the gene to remain intact.
Interestingly, a 2’-fluoro modified ASO, recruits interleukin
enhancer-binding 2 and 3 complex (ILF2/3) to bind to the
active site causing the exon to be skipped [35]. Currently, the
ASO-10-27 MOE modified drug demonstrates marked
improvement in clinical trials from the mechanism of exon 7
splicing, as this therapy is currently in clinical phase III
trials. However, it is worth nothing that other chemical
modifications are being studied for future use as a new
mechanism for treatment of SMA along with a wide variety
of other potential disease targets.
Factor XI for Thrombosis
Thrombosis (blood clotting) is a major health issue that
may arise from adverse drug reactions, post-surgical
outcomes, stroke, myocardial infarction, or spontaneously by
ill-defined mechanisms. Factor XI is a serine protease
enzyme that is converted to Factor XIa and directly involved
in the coagulation cascade [37]. This enzyme has been
targeted as a potential upstream inhibitor for thrombosis by
ASO-based gene knock-down therapy utilizing a second
generation ASO (FXI-ASO), which has a 2’-O-MOE RNA
modification coinciding with the PS modification allowing
for this ASO to stably be incorporated into the cell for
targeting factor XI mRNA [37]. The rationale for targeting this

specific factor, was the lack of potential bleeding events,
while also lowering the rate of blood clotting. FXI-ASO was
tested in animals and showed no disruption of homeostasis
during knock-down of Factor XI protein activity by over
90% [38]. FXI-ASO is able to bind to mRNA of factor XI in
the liver, specifically in the hepatocytes which is the primary
site of factor XI formation [39]. The hepatic inhibition leads to
a downstream reduction of plasma factor XI levels.
Currently, this drug is in phase II of clinical trials, as it has
been subject to a human open-label phase study, by which no
treatment disguise or placebo is used [40]. This study showed
that at higher doses, there were no reported toxicity events,
and all noted side-effects were negligible, as the patients
responded to positive anti-coagulation without increased
bleeding risk, [40] which is novel to most anti-coagulant based
treatments. At this time, more work needs to be done since
ASO targeting of hepatic factor XI production has shown
promising results for the future treatment of patients with
high risk of suffering from thrombosis.
Hyperlipoproteinemia/Apolipoproteinemia
Hyperlipoproteinemia,
also
known
as
hypercholesterolemia, is a condition in which increased
amounts of serum low density lipoprotein (LDL) cholesterol
accumulates in the blood stream. This is traditionally a
precursor for cardiovascular diseases, as well as plaque
formation based on the age at which onset occurs [41]. There
are a variety of factors that contribute to a patient diagnosed
with this disease, though there is a genetic predisposition,
known as familial hypercholesterolemia (FH). FH is thought
to be most commonly associated with a mutation in the LDL
receptor (LDLR) gene in patients expressing either
heterozygous, with one allele being mutated, or homozygous
genes, with both alleles mutated [42]. Although the LDLR
mutation is very common in FH diagnoses, there are also
reported cases indicating that a mutation in apolipoprotein B
(ApoB) can also cause FH, with phenotypic similarities that
make diagnosis virtually indistinguishable from other causes.
FH caused by dysfunctional ApoB is found in approximately
1 in 500 people in Western cultures [43]. A common form of
treatment for FH is to prescribe statins, which effectively
reduce cholesterol synthesis by HMG-CoA reductase,
although most patients require additional drug therapy and
lifestyle changes [42].
With the advances in ASO technology, a RNase H1 active
second generation 2’-O-MOE PS-ASO (Mipomersen) was
developed that complements the coding region of ApoB
mRNA located at position 3249-3268 of the mRNA [44].
Following subcutaneous injection, Mipomersen is distributed
across a wide variety of tissues including the liver, and it has
been determined through clinical studies that it effectively
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reduces plasma LDL cholesterol levels. Additionally, it has
been shown that Mipomersen does not have deleterious
effects on high density lipoproteins (HDL), which are
important for lipid transport to liver and other steroidogenic
organs [44]. Due to the success of Mipomersen by both low
toxicity reports and high apolipoprotein B inhibition, it has
been approved by the FDA for clinical use for FH treatment
[9]
. Currently, with more mutations being discovered that lead
to LDL Cholesterol accumulation, additional ASO-based
drugs are currently being developed in the clinical pipeline.
A few of these are: Ionis-APO(a)Rx which is a second
generation (2’-O-MOE) drug that is currently in clinical trials
for treatment of the protein apolipoprotein A, which is
implicated in cardiovascular disease and aortic valve stenosis
[45]
and Apolipoprotein C-III and its role in plasma
triglyceride levels. Currently, improvements and testing for
2’-O-MOE ASO Ionis 304801 (Apo-C3Rx) is in refinement to
reduce plasma triglyceride levels by binding to the the
ApoC3 mRNA to reduce apolipoprotein C-III production [10].
This drug is currently in clinical phase III trials.
Cellular uptake of Phosphorothioate Modified ASOs
The understanding of uptake and clearance of PS-ASOs is
essential to calibrate the dose and pharmacology of
therapeutic ASOs. Cellular endocytosis of ASOs is of high
interest as a high number of targeted proteins are synthesized
by the liver [5, 10, 24]. PS-ASOs, as mentioned previously have
a higher stability based on the chemical modifications,
allowing them to remain intact for cellular uptake. The
rationale for understanding the pharmacokinetics of ASOs is
to correlate effective dose with clearance rates to optimize
effectiveness while reducing potentially harmful side-effects.
The chemical modifications allow for these drugs to have
high stability, but they are still susceptible to lysosomal
degradation, which allows them to be cleared from the body
after administration [6].
Phosphorothioate Modified ASOs and the Extra-cellular
Matrix
The extra-cellular matrix is an area that could hold the key
for understanding the mechanism for PS-ASO binding and
cellular internalization. Prevoius work has looked at the role
of proteins such as fibroblast growth factor receptors
(FGFR), as a poteintal mechanism of binding for PS-ASOs
based on the polyanionic charge of other molecules (heparin
sulfate and suramin ligands) that bind to these receptors [13,
46]
. It was also of interest based on the high expression of the
FGFRs in the liver, which is a major site of accumulation,
activation, and degradation of ASO molecules [6]. Previous
work that has looked at these proteins as well as many other
heparin binding proteins, such as lamelin and fibronectin

have been identified has poteintal targets for ASO binding
based on the role of ASOs binding to the ECM, as well as
their role in NF-kappaB nuclear transcription regulatory
factor, as a site specific cellular adhesion blocker [47].
Although this reasoning has shown binding of the ASOs to
the proteins, such as FGFR1 as a target for onset obesity by
allele specific single nucleotide polymorphisms [48, 49], a clear
mechanism of internalization from these proteins has
remained elusive. Currently, there are two potential
mechanisms that have begun to explain the internalization of
these molecules; scavenger receptor A, and the stabilin
receptors [5, 6]. Although these two protein receptors are good
candidates to help address the question of internalization of
ASOs, there are still many proteins in the ECM that could
play a significant role in how these drugs are not only
binding to cells, but being internalized as well.
Scavenger Receptor A
Scavenger receptors are a group of LDL recognition and
internalization receptors. Roughly two decades ago,
Bijsterbosch and coworkers detailed how a subset of
scavenger receptor proteins were implicated in
internalization of PS-ASOs into the endothelial cells of the
liver. During the time of this publication there had been three
types of receptor proteins to be analyzed; class A and B in
mammalian systems, and class C which came from
Drosophila [5]. Scavenger receptor A (SR-A) are trimer
proteins that bind and internalize LDL, preferentially
modified by acetylation (in-vitro) or by oxidization (in-vivo)
[50]
. The class A receptors (SR-A), specifically types AI and
AII were well-known which allowed for a comprehensive
investigation for these targets. Their work led to the
conclusion that class A receptors were the primary
internalization mechanism for PS-ASO uptake in the
endothelial cells of the liver [5]. Further in-vitro and in-vivo
studies were performed utilizing SR-A receptors for
internalization, using co-administration of polyanionic
compounds such as dextran sulfate [51]. These compounds
were shown to be competitor polyanionic compounds that
decreased PS-ASO saturation in tissue [51]. Following that
claim, another group at Ionis Pharaceuticals published work
that disputed the claim that SR-As were the primary
scavenger receptors for PS-ASO internalization [52]. That
work investigated the same PS-ASO sequence as previously
reported by use of a SR-A murine knockout which
demonstrated no discernable difference of PS-ASO
internalization between the WT and SR-A KO mice leading
them to speculate that SR-A has no substantial effect on the
pharmacoactivity rates of the PS-ASO [52]. There was
approximately a 50% decrease of high-affinity uptake
mechanisms between the WT and KO cell lines, however,
the authors speculated that other high affinity mechanisms
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could be responsible for at least 50% of the remaining
amount internalized. Currently, no new information
regarding SR-A as a systemic clearance receptor for ASOs is
available.
Stabilin-1 and Stabilin-2
Given the understanding of negatively charged PS-ASO
interactions with heparin binding domains, it was of interest
to determine if the class H scavenger receptors, Stabilin-1
and -2, played a role in PS-ASO systemic clearance and
internalization. Both receptors bind to similar ligands such as
heparin [53], advanced glycation end-products [54], and low
density lipoproteins [55]. These proteins represent a good
model based on their inability to have a strong binding
affinity for phosphodiester-containing nucleic acids [56].
Stabilin receptors are type I receptors that contain seven
Fas-1 domains, 20 epidermal growth factor (EGF) domains
found in 4 clusters, an X-link domain, and a single
transmembrane domain. Stabilin-1 and Stabilin-2 receptors
are expressed in many tissues, particularly in key areas of
PS-ASO accumulation in the body such as the liver, kidney,
spleen adrenal cortex, macrophages, and lymph nodes [57, 58].
One key difference between both Stabilin receptors is that
Stabilin-2 is expressed as two isoforms; the full-length
315-HARE and the 190-HARE which is derived from the
315-HARE by proteolytic cleavage and retains full protein
functionality [59]. Another important distinction is that both
receptors have distinct ligands (hyaluronan and several
chondroitin sulfates for Stabilin-2 and Lactogen and SPARC
for Stabilin-1) and different affinities for shared ligands
(heparin, modified LDLs, etc).
Recent work has indicated that these receptors are
mechanistically significant in PS-ASO cellular endocytosis
and clearance [6]. This work has shown that by incorporation
of 2’-O-MOE modifications with a PS backbone, ASOs are
internalized at a much higher rate in recombinant cells
over-expressing either Stabilin-1 or each of the Stabilin-2
isoforms than in the parental cell line which does not express
either receptor. The content of PS-ASO in liver and spleen of
Stabilin-2 knock-out mice is much lower than in the WT
controls 3 days post-injection [6]. Using competition assays,
similar chemically modified ASOs are internalized by these
receptors, however, the 2’MOE second generation ASO has
the highest rate of internalization by Stabilin receptors.
PS-ASOs are able to bind to the 190-HARE by ionic
interaction, allowing for internalization into the cell [6]. Once
internalized via clathrin mediated endocytosis, the ASOs are
transported via the endosomal pathway for degradation in the
lysosome [6]. The increased rate of PS-ASO internalization in

cell culture experiments also correlated to increased
knock-down activity of the target gene of interest suggesting
that once internalized, the ASO is escaping the endosomal
pathway, leading to increased genetic silencing. Although
recent work demonstrates how Stabilin receptors are
implicated in the internalization of PS-ASO, a detailed
understanding of the mechanism for ASO escape from
endosomes for RNase H mediated mRNA degradation is
lacking.
Conclusion
Recent and continued work of chemical modifications has
allowed for progress of ASO drugs for suppressing gene
expression for therapeutic purposes. Currently, over 35 of
these drugs are either in clinical trials, or have been approved
by the FDA for use against a variety of diseases. Although
much work has been done to increase the selectivity and
potency of these drugs, while decreasing side effects and
toxicity, some of the basic mechanisms for PS-ASO
internalization and activity against their specific targets is
just beginning to be understood. More mechanisitic work in
the basic science is required to determine the trafficking and
activation of productive ASOs in primary cells. Despite these
obstacles, the field of antisense oligonucleotide therapy has
proven to be a promising one for current and future treatment
of genetic disorders.
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